Key clinical point: The addition of low-dose pegylated interferon- a2b (PegIFN- a2b) to dasatinib 3 months after initiation of tyrosine kinase inhibitor was effective and well tolerated without an increased risk for late toxicity in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP).
Major finding: At 5 years, rates of major molecular response (MR), MR4, and MR4.5 were 84.6%, 64.1%, and 51.3%, respectively. No disease progression or CML-related deaths were observed. Grade 2 or higher hematological adverse events were not observed after 12 months. After 24 months, pleural effusion was reported in 10% of patients.
Study details: Findings are from a 5-year follow-up of phase 2 NordCML007 trial including 40 adult patients with newly diagnosed CML-CP who were given upfront dasatinib. Low-dose PegIFN- a2b was added from months 4 to 15 after dasatinib initiation.
Disclosures: This study was sponsored by the Norwegian University of Science and Technology. No disclosures were reported.
Source: Flygt H et al. Eur J Haematol. 2021 Aug 21. doi: 10.1111/ejh.13699 .